ArticleImmunology2001
The regulation of FasL expression during activation-induced cell death (AICD).
Article in Immunology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- An Overview on T-Cell Engagers: The Current Position in Both the Biological and Mathematical Context.Computational and structural biotechnology journal · 2026Review
- Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy.iScience · 2025Article
- Synergistic effect of chimeric antigen receptor modified with Bcl-2 on enhanced solid tumour targeting.Human cell · 2024Article
- 9-cis-retinoic acid signaling in Sertoli cells regulates their immunomodulatory function to control lymphocyte physiology and Treg differentiation.Reproductive biology and endocrinology : RB&E · 2024Article
- Review
- Cytokine Deficiencies in Patients with Long-COVID.Journal of clinical & cellular immunology · 2022Article
- The Immunopathobiology of SARS-CoV-2 Infection.FEMS microbiology reviews · 2021Article
- High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4Journal for immunotherapy of cancer · 2021Article
- Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis.Cancers · 2021Article
- ALG-2 couples T cell activation and apoptosis by regulating proteasome activity and influencing MCL1 stability.Cell death & disease · 2020Article
- Four Cysteine Residues Contribute to Homodimerization of Chicken Interleukin-2.International journal of molecular sciences · 2019Article
- The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.Clinical and experimental immunology · 2011Article
- Negative autoregulation by Fas stabilizes adult erythropoiesis and accelerates its stress response.PloS one · 2011Article
- Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells.Experimental biology and medicine (Maywood, N.J.) · 2010Article
- Mitomycin C induces bystander killing in homogeneous and heterogeneous hepatoma cellular models.Molecular cancer · 2009Article
- Increased spontaneous ex vivo apoptosis and subset alterations in peripheral blood T cells from patients with multiple sclerosis.Journal of clinical immunology · 2006Article
- FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.The Journal of experimental medicine · 2005Article
- Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor.Clinical and diagnostic laboratory immunology · 2002Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation-induced cell death (AICD), a Fas ligand (FasL)-dependent pathway, is important for maintaining T-cell homeostasis. Interleukin-2 (IL-2), an enhancer of AICD, can also enhance FasL expression. However, we show that the level of FasL or FLIP protein did not correlate with the susceptibility to AICD. Some T cells expressed high levels of FasL yet failed to undergo AICD, while others expressed little FasL and were sensitive. AICD susceptibility did not correlate with the kinetics of FasL up-regulation or down-regulation. The down-regulation of FasL can be mediated by a metalloprotease. However, we describe an alternative mechanism for the loss of FasL by endocytosis. Endocytosis inhibitors such as cytochalasins, sodium azide, deoxyglucose, or low temperatures prevented the loss of FasL. KB8301, a metalloprotease inhibitor had no effect on the loss of FasL or AICD in the T cells. Enhancing FasL expression was not crucial for AICD and the down-regulation of FasL proceeded via endocytosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.